166 related articles for article (PubMed ID: 21245749)
21. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological potentials for activating the fibrinolytic system].
Markwardt F
Z Gesamte Inn Med; 1984 May; 39(10):209-13. PubMed ID: 6380126
[TBL] [Abstract][Full Text] [Related]
23. [Thrombolytic therapy].
Matsuoka M
Saishin Igaku; 1968 Dec; 23(12):2612-20. PubMed ID: 4239635
[No Abstract] [Full Text] [Related]
24. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
[TBL] [Abstract][Full Text] [Related]
25. Serine-proteases as plasminogen activators in terms of fibrinolysis.
Flemmig M; Melzig MF
J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
27. Starase: A bi-functional fibrinolytic protease from hepatic caeca of Asterina pectinifera displays antithrombotic potential.
Choi JH; Sapkota K; Kim S; Kim SJ
Biochimie; 2014 Oct; 105():45-57. PubMed ID: 24977934
[TBL] [Abstract][Full Text] [Related]
28. The plasmin heavy chain-urokinase conjugate: a specific thrombolytic agent.
Nakayama Y; Shinohara M; Tani T; Kawaguchi T; Furuta T; Izawa T; Kaise H; Miyazaki W; Nakano Y
Thromb Haemost; 1986 Dec; 56(3):364-70. PubMed ID: 2951892
[TBL] [Abstract][Full Text] [Related]
29. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review.
Wong SC; Capone A
Retina; 2013 Feb; 33(2):339-48. PubMed ID: 23001068
[TBL] [Abstract][Full Text] [Related]
30. Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Marder VJ
Thromb Res; 2009; 123 Suppl 4():S56-61. PubMed ID: 19303506
[TBL] [Abstract][Full Text] [Related]
31. Antithrombotic effects of a newly purified fibrinolytic protease from Urechis unicinctus.
Bi Q; Han B; Feng Y; Jiang Z; Yang Y; Liu W
Thromb Res; 2013 Aug; 132(2):e135-44. PubMed ID: 23891134
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
33. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
[TBL] [Abstract][Full Text] [Related]
34. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
35. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
[TBL] [Abstract][Full Text] [Related]
36. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke.
Thijs VN; Peeters A; Vosko M; Aichner F; Schellinger PD; Schneider D; Neumann-Haefelin T; Röther J; Davalos A; Wahlgren N; Verhamme P
Stroke; 2009 Dec; 40(12):3789-95. PubMed ID: 19834019
[TBL] [Abstract][Full Text] [Related]
37. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
38. A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis.
Verhamme P; Jerome M; Goossens G; Devis J; Maleux G; Stas M
J Thromb Thrombolysis; 2009 Nov; 28(4):477-81. PubMed ID: 19225865
[TBL] [Abstract][Full Text] [Related]
39. Concepts of clot lysis.
Francis CW; Marder VJ
Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
[TBL] [Abstract][Full Text] [Related]
40. The fibrinolytic system and its pharmacologic activation for thrombolysis.
Sherry S
Cardiol Clin; 1987 Feb; 5(1):1-11. PubMed ID: 2951008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
